TEZSPIRE 210 mg, solution for injection in a pre-filled syringe syringe, 1.91 ml
Active ingredients: Tezepelumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1.91 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TEZSPIRE 210 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 1,91 mL
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 May 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68954908CIP73026159CIP133400930261590Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉZÉPELUMABsolution | 210 mg · une seringue préremplie | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.